Shenzhen Eureka Biotechnology

Shenzhen Eureka Biotechnology, also known as EurekaBio, is a leading upstream technology provider in the cell and gene therapy (CGT) sector. Founded in 2014 and headquartered in Shenzhen, China, the company focuses on developing automated equipment and innovative bioprocessing solutions to address the high costs and complexities of CGT manufacturing. Its core offerings include the EuLV™ Lentiviral Vector Production System, which utilizes stable producer cell lines to enable large-scale, plasmid-free viral vector production, and the CellSep® series of automated, closed cell processing systems. EurekaBio's technologies have been integrated into numerous clinical programs, including the first FDA IND-approved CAR-T therapy to use a stable lentiviral production system. The company aims to empower the global CGT industry by providing standardized, efficient, and cost-effective manufacturing platforms.